全文获取类型
收费全文 | 53529篇 |
免费 | 5755篇 |
国内免费 | 90篇 |
专业分类
耳鼻咽喉 | 688篇 |
儿科学 | 1559篇 |
妇产科学 | 1475篇 |
基础医学 | 8339篇 |
口腔科学 | 1142篇 |
临床医学 | 7183篇 |
内科学 | 9944篇 |
皮肤病学 | 734篇 |
神经病学 | 4622篇 |
特种医学 | 1600篇 |
外国民族医学 | 1篇 |
外科学 | 6922篇 |
综合类 | 969篇 |
一般理论 | 43篇 |
预防医学 | 5763篇 |
眼科学 | 820篇 |
药学 | 4206篇 |
中国医学 | 77篇 |
肿瘤学 | 3287篇 |
出版年
2022年 | 430篇 |
2021年 | 1087篇 |
2020年 | 758篇 |
2019年 | 1114篇 |
2018年 | 1195篇 |
2017年 | 898篇 |
2016年 | 1054篇 |
2015年 | 1073篇 |
2014年 | 1434篇 |
2013年 | 2087篇 |
2012年 | 2869篇 |
2011年 | 2916篇 |
2010年 | 1589篇 |
2009年 | 1431篇 |
2008年 | 2397篇 |
2007年 | 2529篇 |
2006年 | 2408篇 |
2005年 | 2306篇 |
2004年 | 2171篇 |
2003年 | 2063篇 |
2002年 | 2043篇 |
2001年 | 1592篇 |
2000年 | 1613篇 |
1999年 | 1404篇 |
1998年 | 663篇 |
1997年 | 529篇 |
1996年 | 446篇 |
1995年 | 482篇 |
1994年 | 453篇 |
1993年 | 411篇 |
1992年 | 1126篇 |
1991年 | 1060篇 |
1990年 | 1033篇 |
1989年 | 950篇 |
1988年 | 873篇 |
1987年 | 902篇 |
1986年 | 870篇 |
1985年 | 891篇 |
1984年 | 709篇 |
1983年 | 605篇 |
1982年 | 428篇 |
1981年 | 355篇 |
1980年 | 364篇 |
1979年 | 584篇 |
1978年 | 442篇 |
1977年 | 366篇 |
1976年 | 369篇 |
1974年 | 381篇 |
1973年 | 335篇 |
1972年 | 340篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
3.
4.
Byrne Emma Abel Stephen Yu Alexander Shepard Matthew Karlovits Stephen M. Wegner Rodney E. 《Journal of neuro-oncology》2022,157(1):197-205
Journal of Neuro-Oncology - Adjuvant radiation is often used in patients with low grade gliomas with high-risk characteristics with a recommended dose of 45–54 Gy. We used the... 相似文献
5.
6.
Jasmine Poonian Nicola Walsham Thomas Kilner Elizabeth Bradbury Kristen Brooks Emma West 《Emergency medicine Australasia : EMA》2020,32(4):700-702
Emergency Medicine staff in Australia and New Zealand are at the forefront of the healthcare response to COVID‐19. This article describes a well‐being plan for ED staff that has been devised to mitigate against the negative psychological impact of the COVID‐19 pandemic. 相似文献
7.
Mohid S Khan Thomas Walter Amy Buchanan-Hughes Emma Worthington Lucie Keeber Marion Feuilly Enrique Grande 《World journal of gastroenterology : WJG》2020,26(30):4537-4556
BACKGROUND Approximately 20% of patients with neuroendocrine tumours(NETs) develop carcinoid syndrome(CS),characterised by flushing and diarrhoea.Somatostatin analogues or telotristat can be used to control symptoms of CS through inhibition of serotonin secretion.Although CS is often the cause of diarrhoea among patients with gastroenteropancreatic NETs(GEP-NETs),other causes to consider include pancreatic enzyme insufficiency(PEI),bile acid malabsorption and small intestinal bacterial overgrowth.If other causes of diarrhoea unrelated to serotonin secretion are mistaken for CS diarrhoea,these treatments may be ineffective against the diarrhoea,risking detrimental effects to patient quality of life.AIM To identify and synthesise qualitative and quantitative evidence relating to the differential diagnosis of diarrhoea in patients with GEP-NETs.METHODS Electronic databases(MEDLINE,Embase and the Cochrane Library) were searched from inception to September 12,2018 using terms for NETs and diarrhoea.Congresses,systematic literature review bibliographies and included articles were also hand-searched.Any study designs and publication types were eligible for inclusion if relevant data on a cause(s) of diarrhoea in patients with GEP-NETs were reported.Studies were screened by two independent reviewers at abstract and full-text stages.Framework synthesis was adapted to synthesise quantitative and qualitative data.The definition of qualitative data was expanded to include all textual data in any section of relevant publications.RESULTS Forty-seven publications(44 studies) were included,comprising a variety of publication types,including observational studies,reviews,guidelines,case reports,interventional studies,and opinion pieces.Most reported on PEI on/after treatment with somatostatin analogs;9.5%-84% of patients with GEP-NETs had experienced steatorrhoea or confirmed PEI.Where reported,14.3%–50.7% of patients received pancreatic enzyme replacement therapy.Other causes of diarrhoea reported in patients with GEP-NETs included bile acid malabsorption(80%),small intestinal bacterial overgrowth(23.6%-62%),colitis(20%) and infection(7.1%).Diagnostic approaches included faecal elastase,breath tests,tauroselcholic(selenium-75) acid(Se HCAT) scan and stool culture,although evidence on the effectiveness or diagnostic accuracy of these approaches was limited.Assessment of patient history or diarrhoea characteristics was also reported as initial approaches for investigation.From the identified evidence,if diarrhoea is assumed to be CS diarrhoea,consequences include uncontrolled diarrhoea,malnutrition,and perceived ineffectiveness of CS treatment.Approaches for facilitating differential diagnosis of diarrhoea include improving patient and clinician awareness of non-CS causes and involvement of a multidisciplinary clinical team,including gastroenterologists.CONCLUSION Diarrhoea in GEP-NETs can be multifactorial with misdiagnosis leading to delayed patient recovery and inefficient resource use.This systematic literature review highlights gaps for further research on prevalence of non-CS diarrhoea and suitability of diagnostic approaches,to determine an effective algorithm for differential diagnosis of GEP-NET diarrhoea. 相似文献
8.
9.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献10.
Ali Mobasheri Csaba Matta Ilona Uzielienè Emma Budd Pablo Martín-Vasallo Eiva Bernotiene 《Joint, bone, spine : revue du rhumatisme》2019,86(1):29-35
Chondrocytes are the main cells in the extracellular matrix (ECM) of articular cartilage and possess a highly differentiated phenotype that is the hallmark of the unique physiological functions of this specialised load-bearing connective tissue. The plasma membrane of articular chondrocytes contains a rich and diverse complement of membrane proteins, known as the membranome, which defines the cell surface phenotype of the cells. The membranome is a key target of pharmacological agents and is important for chondrocyte function. It includes channels, transporters, enzymes, receptors, and anchors for intracellular, cytoskeletal and ECM proteins and other macromolecular complexes. The chondrocyte channelome is a sub-compartment of the membranome and includes a complete set of ion channels and porins expressed in these cells. Many of these are multi-functional proteins with “moonlighting” roles, serving as channels, receptors and signalling components of larger molecular assemblies. The aim of this review is to summarise our current knowledge of the fundamental aspects of the chondrocyte channelome, discuss its relevance to cartilage biology and highlight its possible role in the pathogenesis of osteoarthritis (OA). Excessive and inappropriate mechanical loads, an inflammatory micro-environment, alternative splicing of channel components or accumulation of basic calcium phosphate crystals can result in an altered chondrocyte channelome impairing its function. Alterations in Ca2+ signalling may lead to defective synthesis of ECM macromolecules and aggravated catabolic responses in chondrocytes, which is an important and relatively unexplored aspect of the complex and poorly understood mechanism of OA development. 相似文献